Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Bisaramil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisaramil SCHEMBL6995785 | 0.97 | L3MBTL1 (0.49) | L3MBTL1GLALMNACYP2D6CYP2C19 | |
| Bisaramil SCHEMBL333325 | 0.97 | L3MBTL1 (0.49) | L3MBTL1GLALMNACYP2D6CYP2C19 | |
| Bisaramil SCHEMBL11046247 | 0.96 | L3MBTL1 (0.51) | L3MBTL1GLALMNACYP2D6CYP2C19 | |
| Bisaramil SCHEMBL8185946 | 0.96 | L3MBTL1 (0.51) | L3MBTL1GLALMNACYP2D6CYP2C19 | |
| Bisaramil SCHEMBL9058599 | 0.96 | L3MBTL1 (0.51) | L3MBTL1GLALMNACYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL11049178 | 0.90 | L3MBTL1 (0.48) | L3MBTL1GLALMNACYP2D6CYP2C19 | |
| SCHEMBL11053024 | 0.88 | L3MBTL1 (0.57) | L3MBTL1GLALMNACYP2D6CYP2C19 | |
| SCHEMBL11046189 | 0.85 | OPRM1 (0.48) | CHRNA7MEN1KMT2A | |
| SCHEMBL11044803 | 0.83 | SCN1A (0.53) | L3MBTL1LMNATSHRCHRNB2CHRNA4 | |
| SCHEMBL11048659 | 0.82 | L3MBTL1 (0.46) | L3MBTL1GLALMNACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6190691-B1 | ADMINISTERING FORMULATION COMPRISING TUMOR NERCOSIS FACTOR (TNF) PRODUCTION-INHIBITORY AMOUNT OF A COMPOUND SELECTED FROM LOPERAMIDE AND DIPHENOXYLATE TO MAMMAL | ADOLOR CORPORATION | 2001-02-20 | — | — | US | disclosed |
| US-5962477-A | USING LOPERAMIDE | ADOLOR CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0937460-A2 | Use of an antidiarrheal for the manufacture of a medicament for the treatment of inflammatory conditions | Adolor Corporation (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0757558-A4 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORP (US) | 1999-06-16 | — | — | EP | disclosed |
| EP-0757558-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995027510-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |